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Abstract
Introduction: Osteoarthritis (OA) is the most common degenerative joint disease that is involved in the
degradation of articular cartilage. The exact etiology of OA is not completely understood. CCN4 is related to up-
regulation in the cartilage of patients with osteoarthritis. Previous studies have shown that CCN4 might be
associated with the pathogenesis of OA, but the exact signaling pathways in CCN4-mediated IL-6 expression in
synovial fibroblasts (SF) are largely unknown. Therefore, we explored the intracellular signaling pathway involved in
CCN4-induced IL-6 production in human synovial fibroblast cells.
Methods: CCN4-induced IL-6 production was assessed with quantitative real-time qPCR and ELISA. The mechanisms of
action of CCN4 in different signaling pathways were studied by using Western blotting. Neutralizing antibodies of
integrin were used to block the integrin signaling pathway. Luciferase assays were used to study IL-6 and NF-B
promoter activity. Immunocytochemistry was used to examine the translocation activity of p65.
Results: Osteoarthritis synovial fibroblasts (OASFs) showed significant expression of CCN4 and the expression was
higher than in normal SFs. OASF stimulation with CCN4 induced concentration- and time-dependent increases in
IL-6 production. Pretreatment of OASFs with avb5 but not a5b1 and avb3 integrin antibodies reduced CCN4-
induced IL-6 production. CCN4-mediated IL-6 production was attenuated by PI3K inhibitor (LY294002 and
Wortmannin), Akt inhibitor (Akti), and NF-B inhibitor (PDTC and TPCK). Stimulation of cells with CCN4 also
increased PI3K, Akt, and NF-B activation.
Conclusions: Our results suggest that CCN4 activates avb5 integrin, PI3K, Akt, and NF-B pathways, leading to
up-regulation of IL-6 production. According to our results, CCN4 may be an appropriate target for drug intervention
in OA in the future.
Introduction
Osteoarthritis (OA) is the most common degenerative
disease of the synovial joint that involves the degradation
of articular cartilage, subchondral bone sclerosis, abnor-
mal bone remodeling, osteophyte formation, and chronic
inflammation of the synovial membrane [1,2]. Typical
symptoms of OA include joint pain, stiffness, swelling,
and muscle weakness. The principal forms of treatment
include pain management and replacement surgery.
Unfortunately, the exact etiology of OA is not well
understood [3]. The synovial membrane is responsible
for the inflammatory reaction leading to macrophage-
derived proinflammatory cytokines, such as IL-1b, IL-6,
IL-8 and TNF-a, that promote inflammation, neovascu-
larization and cartilage degradation via activation of
matrix-degrading enzymes, such as matrix metalloprotei-
nases (MMPs) [4-6].
Some evidence suggests that development of OA is
often accompanied by inflammation [7,8] and elevated
levels of cytokines, such as IL-6 which is a regulator of
inflammation in OA. IL-6 has numerous biological activ-
ities and is considered as the major player that regulates
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the innate immune response, haemopoiesis, and inflam-
mation. Numerous studies have demonstrated that IL-6
activates osteoclasts and stimulates the synovium to
release MMPs that induce cartilage destruction in OA
[9]. A clinical trial showed that IL-6 seems to be the
important proinflammatory cytokine involved in the
pathophysiology of OA [10,11]. OA patients have a
higher concentration of IL-6 in their whole blood com-
pared with that of normal subjects [12]. Similarly, chon-
drocytes produce low levels of IL-6 under normal
conditions. Therefore, these data suggest that IL-6 plays
an important role during OA pathogenesis. Several con-
sensus sequences, including those for NF-B, CREB, NF-
IL-6, and AP-1 in the 5’-promoter region of the IL-6
gene, have been identified as regulatory sequences that
induce IL-6 in response to various stimuli [13,14]. NF-
B, an important transcription factor that regulates IL-6
expression, is a heterodimer of transcription factor p65
and transcription factor p50. In a resting state, this dimer
is associated with IBs to retain NF-B in the cytosol.
IB kinase is activated through stimulation by cytokines
and bacterial products. Phosphorylation of IBa at Ser32
and Ser36 and IBa at Ser19 and Ser23 produces ubiquiti-
nation of IBa/b at lysine residues and degradation by
the 26S proteasome [15,16].
WNT-inducible signaling pathway protein-1 (WISP-1,
also known as CCN4) belongs to the CCN gene family,
which contains cysteine-rich 61 (Cyr61/CCN1), connective
tissue growth factor (CTGF/CCN2), nephroblastoma over-
expressed (NOV/CCN3), WISP-1/CCN4, WISP-2/CCN5,
and WISP-3/CCN6. This gene family encodes secreted
proteins that interact with the extracellular matrix and
have important roles in migration, adhesion, proliferation,
apoptosis, survival, inflammation, and injury repair [17,18].
In a recent study, CCN4 acts in an autocrine manner to
accelerate cell growth, induce morphological transforma-
tion, increase saturation density, and promote tumorigen-
esis in normal fibroblasts [19]. In addition, CCN4 is
strongly upregulated in the cartilage of patients with OA
which can elicit the release of MMPs and aggrecanase
from macrophages and chondrocytes which causes carti-
lage damage [20,21].
Previous studies have shown that CCN4 might be asso-
ciated with the pathogenesis of OA [20]. However, the
role of CCN4 in IL-6 production in osteoarthritis synovial
fibroblasts (OASFs) has not been extensively studied. In
the present study, we explored the intracellular signaling
pathway involved in CCN4-induced IL-6 production in
human synovial fibroblast (SF) cells. The results showed
that CCN4 activates avb5 integrin, PI3K, Akt, and NF-B
pathways, leading to up-regulation of IL-6 expression.
According to our results, CCN4 may be an appropriate
target for drug intervention in OA in the future.
Materials and methods
Materials
Protein A/G beads, anti-mouse and anti-rabbit immuno-
globulin G (IgG) conjugated horseradish peroxidase, rab-
bit polyclonal antibodies specific for PI3K, Akt, IKKa/b,
IB, p65, and b-actin were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal
antibody specific for PI3K phosphorylated at Tyr458/199,
Akt phosphorylated at ser473, IKKa/b phosphorylated at
ser176/180, IBa phosphorylated at ser32/36 and p65 phos-
phorylated at ser536 were purchased from Cell Signaling
and Neuroscience (Danvers, MA, USA). Mouse monoclo-
nal antibody specific for avb3, avb5, and a5b1 integrin
were purchased from Chemicon (Temecula, CA, USA).
Pyrrolidine-dithiocarbamate (PDTC), L-1-tosylamido-2-
phenylenylethyl chloromethyl ketone (TPCK), LY294002,
Wortmannin, and pan-Akt inhibitor (1L-6-hydroxy-
methyl-chiro-inositol-2-((R)-2-O-methyl-3-O-octadecyl-
carbonate) were purchased from Calbiochem (San Diego,
CA, USA). IL-6 enzyme immunoassay kit was purchased
from Cayman Chemical (Ann Arbor, MI, USA). The
recombinant human CCN4 was purchased from Pepro-
Tech (Rocky Hill, NJ, USA). ON-TARGETplus siRNA of
av integrin, b5 integrin, p110 and control were pur-
chased from Dharmacon Research (Lafayette, CO, USA).
The NF-B luciferase plasmid was purchased from Stra-
tagene (La Jolla, CA, USA). The p85 and Akt1 (Akt1
K179A) dominant-negative mutants were gifts from Dr.
W.M. Fu (National Taiwan University, Taipei, Taiwan).
The human IL-6 promoter construct pIL6-luc651 (-651/
+1), AP-1 site mutation (pIL6-luc651ΔAP1), NF-B site
mutation (pIL6-luc651ΔNF-B), and C/EBP-b site muta-
tion (pIL6-luc651ΔC/EBP-b) [22] were gifts from Dr. Oliver
Eickelberg (Ludwig Maximilians University Munich,
Munich, Germany). The pSV-b-galactosidase vector and
the luciferase assay kit were purchased from Promega
(Madison, MA, USA). All other chemicals were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
Cell cultures
Written informed consent was obtained from all patients
and the study was approved by the Institutional Review
Board of Shin Kong Wu Ho-Su Memorial Hospital.
Human SFs were isolated by collagenase treatment of
synovial tissue samples obtained from 32 patients with
OA during knee-replacement surgeries and 18 samples of
nonarthritic synovial tissues obtained at arthroscopy after
trauma/joint derangement. Fresh synovial tissues were
minced and digested in a solution of collagenase and
DNase. Isolated fibroblasts were filtered through 70-µm
nylon filters. The cells were grown on plastic cell culture
dishes in 95% air-5% CO2 with (D)MEM (Life Technolo-
gies, Grand Island, NY, USA) that was supplemented
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with 20 mM HEPES and 10% heat-inactivated fetal
bovine serum (FBS), 2 mM glutamine, 100 U/ml penicil-
lin, and 100 µg/ml streptomycin (pH adjusted to 7.6).
Fibroblasts from passages four to nine were used for the
experiments [23,24]. The cells from different patients
were treated with CCN4 separately. All studies were car-
ried out on cells from at least four patients. Results are
from four independent experiments [2].
Measurement of IL-6 production
Human SFs were cultured in 24-well culture plates.
After reaching confluence, cells were treated with CCN4
and then incubated in a humidified incubator at 37°C
for 24 hours. For examination of the downstream signal-
ing pathways involved in CCN4 treatment, cells were
pretreated with various inhibitors for 30 minutes (these
inhibitors did not affect cell viability; Additional file 1,
Figure S1) before CCN4 (30 ng/ml) administration.
After incubation, the medium was removed and stored
at -80°C until assay. IL-6 in the medium was assayed
using the IL-6 enzyme immunoassay kits, according to
the procedure described by the manufacturer.
Quantitative real-time PCR
Total RNA was extracted from SFs using a TRIzol kit
(MDBio Inc., Taipei, Taiwan). The reverse transcription
reaction was performed using 2 µg of total RNA that
was reverse transcribed into cDNA using oligo (dT) pri-
mer [25,26]. The quantitative real-time PCR (qPCR)
analysis was carried out using Taqman® one-step PCR
Master Mix (Applied Biosystems, Foster City, CA).
cDNA templates (2 µl) were added per 25-µl reaction
with sequence-specific primers and Taqman® probes.
Sequences for all target gene primers and probes were
purchased commercially (b-actin was used as internal
control) (Applied Biosystems). The qPCR assays were
carried out in triplicate on a StepOnePlus sequence
detection system. The cycling conditions were 10-minute
polymerase activation at 95°C, followed by 40 cycles at
95°C for 15 seconds and 60°C for 60 seconds. The thresh-
old was set above the non-template control background
and within the linear phase of the target gene amplifica-
tion to calculate the cycle number at which the transcript
was detected (denoted CT) [27].
Western blot analysis
Cellular lysates were prepared as described previously
[28,29]. Proteins were resolved on SDS-PAGE and trans-
ferred to immobilon polyvinyldifluoride (PVDF) mem-
branes. The blots were blocked with 4% BSA for 1 hour at
room temperature and then probed with rabbit anti-
human antibodies against PI3K, Akt, IKKa/b and IB, p65,
(1:1000) for 1 hour at room temperature. After three
washes, the blots were subsequently incubated with donkey
anti-rabbit peroxidase-conjugated secondary antibody
(1:3000) for 1 hour at room temperature. The blots were
visualized by enhanced chemiluminescence with Kodak
X-OMAT LS film (Eastman Kodak, Rochester, NY, USA).
Quantitative data were obtained using a computing densit-
ometer and ImageQuant software (Molecular Dynamics,
Sunnyvale, CA, USA).
Transfection and reporter gene assay
Human SFs were co-transfected with 0.8 µg luciferase
plasmid and 0.4 µg b-galactosidase expression vector.
Fibroblasts were grown to 80% confluence in 12 well
plates and were transfected the following day with Lipofec-
tamine 2000 (LF2000; Invitrogen, Carlsbad, CA, USA).
DNA and LF2000 were premixed for 20 minutes and then
applied to the cells (the transfection efficiency is more
than 90%, confirmed by transfection with Green fluores-
cent protein (GFP) -expressing plasmid; Additional file 1,
Figure S2). After 24 hours transfection, cells were incu-
bated with the indicated agents. After a further 24-hour
incubation, the media were removed and the cells were
washed once with cold PBS. To prepare lysates, 100 µl
reporter lysis buffer (Promega) was added to each well,
and the cells were scraped from the dishes. The superna-
tant was collected after centrifugation at 13,000 rpm for
two minutes. Aliquots of cell lysates (20 µl) containing
equal amounts of protein (20 µg to 30 µg) were placed
into wells of an opaque black 96-well microplate. An equal
volume of luciferase substrate was added to all samples
and luminescence was measured in a microplate lumin-
ometer. The value of luciferase activity was normalized to
transfection efficiency monitored by the co-transfected
b-galactosidase expression vector [30].
Immunofluorescence staining
Cells were cultured in 12 mm coverslips. After treatment
with CCN4, cells were fixed with 4% paraformaldehyde at
room temperature. Thirty minutes later, 4% nonfat milk in
PBS containing 0.5% Triton X-100 was added to the cells.
The cells were then incubated with rabbit anti-p65 (1:100)
and fluorescein isothiocyanate (FITC)-conjugated goat
anti-rabbit secondary antibody (1:500; Leinco Technology
Inc., St Louis, MO, USA) for 1 hour, respectively. The
FITC was detected using a Zeiss fluorescence microscope
[31].
Statistics
The values reported are means ± standard error of the
mean (SEM). Statistical analysis between two samples
was performed using Student’s t-test. Statistical compar-
isons of more than two groups were performed using
one-way analysis of variance (ANOVA) with Bonferro-
ni’s post-hoc test. In all cases, P <0.05 was considered
significant.
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Results
CCN4 induces IL-6 production in human synovial
fibroblasts
It has been reported that CCN4 plays an important role
during OA pathogenesis. [21]. First, we examined human
SF tissues for the expression of CCN4 by using Western
blotting. The expression of CCN4 in patients with OA was
significantly higher than in controls (Figure 1A). Next, we
directly applied CCN4 in OASFs and examined the
expression of IL-6 (an important inflammatory response
gene). Treatment of OASFs with CCN4 (1 to 30 ng/ml)
for 24 hours induced IL-6 production in a concentration-
dependent manner (Figure 1B), and this induction
occurred in a time-dependent manner (Figure 1C). In
addition, stimulation of cells with CCN4 also increased
mRNA expression of IL-6 in a concentration- and time-
dependent manner (Figure 1D and 1E). On the other
hand, treatment of OASF cells with CCN4 (1 to 30 ng/ml)
for 24 hours also induced IL-6 protein expression (Figure
1F). To confirm this stimulation specific mediation by
CCN4 without endotoxin contamination, polymyxin B, a
lipopolysaccharide inhibitor, was used. We found that
polymyxin B (1 μM) did not affect CCN4-induced IL-6
expression (Figure 1G). Therefore, CCN4 used in this
study is endotoxin free. In contrast, CCN4 did not affect
IL-6 expression in normal SFs (Figure 1B to 1F). There-
fore, OASFs are more sensitive to CCN4 than normal SFs.
We also investigated whether CCN4 induced other
inflammtory cytokines (TNF-a and IL-1b) and MMPs
expression in human SFs. Stimulation of cells with CCN4
increased MMP-2 and -9 but not -1, -3, -7,-12, and -13
expression (Figure 1H). In addition, CCN4 also enhanced
the expression of TNF-a and IL-1b in human SFs (Figure
1H).
Involvement of avb5 integrin in CCN4 induced IL-6
production
Previous study has shown that the CCN family affects cell
functions by binding to cell surface integrin receptors [32].
Therefore, we hypothesized that the integrin signaling
pathway might be involved in CCN4-induced IL-6 produc-
tion. Pretreatment of OASFs with avb5 integrin monoclo-
nal antibody (mAb; 5 µg/ml) for 30 minutes markedly
inhibited CCN4-induced IL-6 production (Figure 2A),
whereas a5b1 and avb3 integrin receptor-specific mAb or
control IgG did not have the same effect. In addition, pre-
treatment of OASF cells with avb5 integrin mAb reduced
CCN4-induced IL-6 expression (Figure 2B, C). To further
confirm CCN4 induced IL-6 production through avb5
integrin, we then examined avb5 integrin expression after
CCN4 treatment. Stimulation of OASFs increased cell
surface and mRNA expression of av and b5 integrin
(Figure 2D, E), suggesting that the amplification loop
strengthens the CCN4-integrin-signaling pathway. To rule
out that the increasing IL-6 production is induced by upre-
gulation of avb5 and not CCN4, the ON-TARGETplus av
and b5 siRNA were used (the design of ON-TARGETplus
siRNA can prevent off-target effects of siRNA). Trans-
fection av and b5 siRNA reduced av and b5 integrin
expression, respectively (Figure 2F). In addition, cotransfec-
tion av and b5 siRNA completely reduced CCN4-mediated
IL-6 expression (Figure 2G). Therefore, the induced CCN4
expression is due to CCN4 but not upregulation of avb5.
In addition, treatment of OASFs with vitronectin (avb5
integrin ligand) also increased IL-6 expression (Figure 2H).
Therefore, activation of avb5 integrin plays a key role in
IL-6 expression in human SFs.
PI3K/Akt signaling pathway is involved in CCN4-mediated
IL-6 production
The PI3K/Akt signaling pathway can be activated by a vari-
ety of factors including insulin and different growth factors
[33,34]. It has been reported that PI3K and Akt activation
regulates the IL-6 expression in OASFs [35]. We then
investigated the role of PI3K in mediating CCN4-induced
IL-6 expression using the specific PI3K inhibitors
LY294002 and Wortmannin. As shown in Figure 3A-C,
CCN4-induced IL-6 expression was markedly attenuated
by pretreatment with LY294002 and Wortmannin for
30 minutes in OASFs. The viability of the human osteosar-
coma cell line MG63 was not affected by LY294002 and
Wortmannin as shown by the 3-(4,5-dmethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay (see Addi-
tional file 1, Figure S1). In addition, transfection of OASFs
with PI3K mutant also reduced CCN4-increased IL-6 pro-
duction (Figure 3D, E). We then directly measured p85
phosphorylation in response to CCN4. Stimulation of cells
led to a significant increase of phosphorylation of p85
(Figure 3F). p85 is one of the regulatory subunits of PI3K.
In contrast, p110 is a catalytic subunit of PI3K. Transfec-
tion cells with p110 siRNA reduced p110 expression and
also reduced CCN4-induced IL-6 expression (Figure 3G).
Therefore, blocked each regulatory or catalytic subunit of
PI3K can abolished CCN4-meidated IL-6 expression.
Furthermore, to examine the crucial role of Akt signaling
in CCN4-induced IL-6 production, we pretreated cells with
Akt inhibitor and antagonized CCN4-increased IL-6 pro-
duction (Figure 4A-C). The viability of the human osteo-
sarcoma cell line MG63 was not affected by AKTi as
shown by the MTT assay [see Additional file 1, Figure S1].
In addition, the Akt mutant also inhibited CCN4-increased
IL-6 production (Figure 4D, E). Akt phosphorylation at
Ser473 by a PI3K-dependent signaling pathway causes enzy-
matic activation [36]. We directly measured Akt phosphor-
ylation in response to CCN4. Treatment of cells with
CCN4 resulted in time-dependent phosphorylation of Akt
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Ser473 (Figure 4F). Based on these results, it appears that
CCN4 acts through the PI3K and Akt-dependent signaling
pathway to enhance IL-6 production in OASFs.
Involvement of NF-B in CCN4 induced IL-6 production
The promoter region of human IL-6 contains three known
cis-regulatory elements including AP-1, C/EBP-b, and NF-
B binding sites [13,14]. Three different IL-6 promoter
constructs containing mutations at NF-B, AP-1, or C/
EBP-b sites, respectively, were generated by site-directed
mutagenesis. We found that CCN4-stimulated IL-6 lucifer-
ase activity was abolished by NF-B-binding site mutation,
but not by AP-1 or C/EBP-b site mutations (Figure 5A).
To examine whether NF-B activation is involved in the
signal transduction pathway leading to IL-6 production
caused by CCN4, the NF-B inhibitor PDTC was used.
Pretreatment of cells with PDTC (5 µM) reduced CCN4-
increased IL-6 expression (Figure 5B-D). Furthermore, the
IB protease inhibitor TPCK (5 µM) also antagonized the
potentiating action of IL-6 (Figure 5B-D). Therefore, the
Figure 1 Concentration- and time-dependent increases in IL-6 production by CCN4. (A) Human synovial fibroblasts (SFs) were obtained
from normal (n = 3) or osteoarthritis patients (n = 3) and examined with western blotting for the expression of CCN4. (B, C) OASFs and normal
SFs were incubated with various concentrations of CCN4 for 24 hours or with CCN4 (30 ng/ml) for 6, 12, or 24 hours. Media were collected to
measure IL-6 production (n = 4). (D, E) OASFs and normal SFs were incubated with various concentrations of CCN4 for 24 hours or with CCN4
(30 ng/ml) for 6, 12, or 24 hours. The mRNA expression of IL-6 was examined by qPCR (n = 4). (F) OASFs and normal SFs were incubated with
various concentrations of CCN4 for 24 hours, and the protein expression of IL-6 was examined by Western blot (n = 3). (G) OASFs were
pretreated with polymyxin B (poly B, 1 μM) for 30 minutes followed by stimulation with CCN4 (30 ng/ml), and IL-6 expression was examined by
qPCR (n = 3). (H) OASFs were incubated with of CCN4 (30 ng/ml), and the mRNA expression was examined by qPCR (n = 3). Results are
expressed as the mean ± SEM. *, P <0.05 compared with control; #, P <0.05 compared with CCN4-treated group. OASFs, osteoarthritis synovial
fibroblasts; SEM, standard error of the mean.
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NF-B binding site is more important than the AP-1 and
C/EBP-b sites in CCN4-induced IL-6 production.
We further examined the upstream molecules involved
in CCN4-induced NF-B activation. Stimulation of cells
with CCN4 induced IKKa/b phosphorylation in a time-
dependent manner (Figure 5E). Transfection of cells with
IKKa or IKKb mutant reduced CCN4-increased IL-6
production (Figure 5B, C). In addition, treatment of cells
with CCN4 also caused IBa phosphorylation in a time-
dependent manner (Figure 5E). Previous studies showed
that p65 Ser536 phosphorylation increases NF-B transac-
tivation [37]. Therefore, the antibody specific against
phosphorylated p65 Ser536 was employed to examine p65
phosphorylation. Treatment of cells with CCN4 for
various time intervals resulted in p65 Ser536 phosphoryla-
tion (Figure 5E). To further confirm that the NF-B
element is involved in the action of CCN4 induced IL-6
expression, we performed transient transfection using the
NF-B promoter-luciferase constructs. OASFs incubated
with CCN4 led to an increase in NF-B promoter activity
in a dose dependent manner (Figure 6A). The increase of
NF-B activity by CCN4 was antagonized by LY294
002, Wortmannin, Akti, TPCK, PDTC, or p85, Akt,
IKKa, and IKKb mutant (Figure 6B, C). Furthermore,
LY294002, Wortmannin and Akti also reduced CCN4-
mediated p65 phosphorylation and translocation into the
Figure 2 avb5 integrin is involved in CCN4-mediated IL-6 production in synovial fibroblast.s (A-C) OASFs were pretreated for 30 minutes
with a5b1, avb3, or avb5 integrin antibody (3 µg/ml) followed by stimulation with CCN4 for 24 hours, and IL-6 expression was examined by qPCR,
ELISA, and Western blot. *, P <0.05 compared with IgG control. (D) OASFs were incubated with various concentrations of CCN4 for 24 hours, and
the cell surface avb5 integrin expression was examined by flow cytometry. (E) OASFs were incubated with CCN4 (30 ng/ml) for 24 hours, and the
mRNA expression of av and b5 integrins was examined by qPCR. (F) OASFs were transfected for 24 hours with av and b5 siRNA, and the integrins
expression was examined by Western blot. (G) OASFs were cotransfected for 24 hours with av and b5 siRNA followed by stimulation with CCN4 for
24 hours, and IL-6 expression was examined by qPCR. (H) OASFs were incubated with vitronectin (10 ng/ml) for 24 hours, and IL-6 expression was
examined by qPCR. Results are expressed as the mean ± SEM (n = 3). *, P <0.05 compared with control; #, P <0.05 compared with the CCN4-treated
group. OASFs, osteoarthritis synovial fibroblasts; IgG, immunoglobulin G; SEM, standard error of the mean.
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Figure 3 PI3K is involved in CCN4-mediated IL-6 production in synovial fibroblasts. (A-C) OASFs were pretreated for 30 minutes with
LY294002 (10 µM) and Wortmannin (5µM) followed by stimulation with CCN4 for 24 hours. Media, total RNA, and protein were collected, and
the expression of IL-6 was analyzed by qPCR, ELISA, and Western blot. (D, E) OASFs were transfected for 24 hours with PI3K mutant followed by
stimulation with CCN4 for 24 hours. Media and total RNA were collected, and the expression of IL-6 was analyzed by qPCR and ELISA. (F) Cells
were incubated with CCN4 for the indicated time intervals, and PI3K phosphorylation was examined by Western blot. Results are expressed as
the mean ± SEM (n = 3). *, P <0.05 compared with control; #, P <0.05 compared with the CCN4-treated group. OASFs, osteoarthritis synovial
fibroblasts; SEM, standard error of the mean.
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nucleus (Figure 6D, E). To examine whether inhibition of
NF-B pathway affects Akt signing in CCN4 treated
cells, OASFs were incubated with PDTC and TPCK, and
Akt phosphorylation was examined. We found that
PDTC and TPCK did not affect CCN4-induced Akt acti-
vation (Figure 6F). Taken together, these data suggest
that activation of the avb5 integrin, PI3K, Akt, and
NF-B pathway is required for the CCN4-induced
increase of IL-6 in human SFs.
Discussion
In addition to related changes in the underlying bone and
joint, OA is mentioned as a heterogeneous group of con-
ditions that are associated with defective integrity of
Figure 4 Akt is involved in the potentiation of IL-6 production by CCN4. (A-C) OASFs were pretreated for 30 minutes with Akti (10 µM)
followed by stimulation with CCN4 for 24 hours. Media, total RNA and protein were collected, and the expression of IL-6 was analyzed by qPCR,
ELISA, and Western blot. (D, E) OASFs were transfected for 24 hours with Akt mutant followed by stimulation with CCN4 for 24 hours. Media
and total RNA were collected, and the expression of IL-6 was analyzed by qPCR and ELISA. (F) Cells were incubated with CCN4 for the indicated
time intervals, and Akt phosphorylation was examined by Western blot. Results are expressed as the mean ± SEM (n = 4). *, P <0.05 compared
with control; #, P <0.05 compared with the CCN4-treated group. OASFs, osteoarthritis synovial fibroblasts; SEM, standard error of the mean.
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articular cartilage [28]. Chronic inflammation of the
synovial membrane contributes to the development of
disease and cartilage degradation through a complex
cytokine network. All the factors responsible for initiating
the degradation and loss of the articular tissues are not
yet completely understood. CCN proteins are considered
to play a pivotal role in inflammation [38,39]. It has been
recently reported that CCN4 is involved in the pathogen-
esis of arthritis, because CCN4 was able to elicit the
release of MMPs and aggrecanase from macrophages and
Figure 5 NF-B is involved in the potentiation of IL-6 production by CCN4. (A) OASFs were transfected with IL-6 luciferase plasmids before
incubation with CCN4 for 24 hours. Luciferase activity was then assayed. (B-D) OASFs were pretreated for 30 minutes with PDTC (10 µM) and TPCK
(10 µM) or transfected for 24 hours with IKKa and IKKb mutant followed by stimulation with CCN4 for 24 hours. Media, total RNA, and total protein
were collected to measure IL-6 by ELISA, qPCR, and Western blot. (E) OASFs were incubated with CCN4 for the indicated time intervals, and p-IKKa/b,
p-IBa, and p-p65 expression was determined by Western blot analysis. Results are expressed as the mean ± SEM (n = 3). *, P <0.05 compared with
control; #, P <0.05 compared with CCN4-treated group. OASFs, osteoarthritis synovial fibroblasts; PDTC, pyrrolidine-dithiocarbamate; SEM, standard
error of the mean, TPCK, L-1-tosylamido-2-phenylenylethyl chloromethyl ketone.
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Figure 6 CCN4 induced NF-B activation through avb5 integrin/PI3K/Akt pathway. (A-C) OASFs were incubated with various concentrations of
CCN4 or pretreated with LY294002, Wortmannin or Akti, PDTC or TPCK for 30 minutes or transfected with PI3K, Akt, IKKa, and IKKb mutant before
exposure to CCN4. NF-B luciferase activity was measured, and the results were normalized to the b-galactosidase activity. (D) OASFs were pretreated
with LY294002, Wortmannin or Akti for 30 minutes followed by stimulation with CCN4 for 60 minutes, and p-p65 expression was examined by
Western blot analysis. (E) OASFs were pretreated with LY294002, Wortmannin or Akti for 30 minutes then stimulated with CCN4 for 120 minutes, and
p65 immunofluorescence staining was examined. (F) OASFs were pretreated with PDTC and TPCK for 30 minutes followed by stimulation with CCN4
for 30 minutes, and p-Akt expression was examined by Western blot analysis. Results are expressed as the mean ± SEM (n = 4). *, P <0.05 compared
with control; #, P <0.05 compared with the CCN4-treated group. OASFs, osteoarthritis synovial fibroblasts; PDTC, pyrrolidine-dithiocarbamate; SEM,
standard error of the mean, TPCK, L-1-tosylamido-2-phenylenylethyl chloromethyl ketone.
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chondrocytes to cause cartilage damage [20,21,40].
Although the involvement of CCN4 in inflammatory
responses has been reported, the molecular mechanisms
underlying CCN4 in IL-6 expression in OA are still
unclear. In this study, we further demonstrated that IL-6
is a target protein for the CCN4 signaling pathway that
regulates the cell inflammatory response. Our results also
indicated that CCN4 induced IL-6 synthesis occurs at 12
hours (Figure 1). However, stimulation of the cells with
CCN4 for 12 hours only increased IL-6 mRNA expres-
sion but not TNF-a and IL-1b [see Additional file 1,
Figure S3]. Therefore, CCN4-induced IL-6 expression is
the direct result of CCN4 but the other cytokines did not
respond to CCN4. We also showed that potentiation of
IL-6 by CCN4 requires activation of the avb5 integrin
receptor, PI3K, Akt, and NF-B signaling pathways.
These findings suggest that CCN4 in OA acts as an indu-
cer of inflammatory cytokines, such as IL-6 and enhances
the inflammatory response.
CCN4 is known to activate integrin, including a5b1,
avb3, and avb5 [41,42]. However, we demonstrated that
avb5 integrin but not a5b1 and avb3 integrin receptor
was required for CCN4-induced IL-6 production. Treat-
ment of cells with avb5, but not a5b1 and avb3 integrin
mAb, inhibited CCN4-induced IL-6 production. In addi-
tion, stimulation of OASFs with CCN4 increased the cell
surface and mRNA expression of av and b5 integrin.
These data suggest that avb5 integrin is involved in
CCN4-induced IL-6 production in human SFs.
It has been reported that a variety of growth factors sti-
mulate the expression of IL-6 genes via signal-transduc-
tion pathways that converge to activate the NF-B
complex of transcription factors and that PI3K/Akt were
involved in the activation of NF-B transcription factors.
However, we demonstrated that CCN4 enhanced PI3K
and Akt phosphorylation in human OASFs. Previous stu-
dies have revealed that CCN4 is a potent activator of
PI3K/Akt, the critical players in cell survival and growth
[43,44]. The CCN4-directed IL-6 production was effec-
tively inhibited by PI3K or Akt inhibitor. This was further
confirmed by the results that showed that the dominant
negative mutant of PI3K and Akt inhibited the enhance-
ment of IL-6 production by CCN4. Our data indicate
that PI3K/Akt may play an important role in the expres-
sion of IL-6 in human OASFs. The MAPK pathway is a
common targeting molecule in integrin-dependent sig-
naling [45]. However, pretreatment of cells with JNK
inhibitor (SP600125) and p38 inhibitor (SB203580) but
not ERK inhibitor (PD98059) reduced CCN4-mediated
IL-6 expression [see Additional file 1, Figure S4]. There-
fore, JNK and p38 but not ERK are also involved in
CCN4-induced IL-6 expression in human SFs.
There are several binding sites for a number of tran-
scription factors including NF-B, CREB, NF-IL-6, and
the AP-1 box in the 5’ region of the IL-6 gene [13,14].
Recent studies on the IL-6 promoter have demonstrated
that IL-6 is induced by several transcription factors in a
highly stimulus-specific or cell-specific manner. The
results of this study show that NF-B activation contri-
butes to CCN4-induced IL-6 production in SFs, and dele-
tion of the NF-B site reduced CCN4-mediated IL-6
promoter activity. Pretreatment of cells with NF-B inhi-
bitors (PDTC and TPCK) also reduced CCN4-increased
IL-6 production. Therefore, the NF-B-binding site is
important in CCN4-induced IL-6 production. It is estab-
lished that the NF-B sequence binds to members of the
p65 and p50 families of transcription factors, and the
results of this study show CCN4-induced p65 phosphory-
lation and nuclear accumulation. Furthermore, using
transient transfection with NF-B-luciferase as an indica-
tor of NF-B activity showed that CCN4 increased
NF-B activation. In addition, LY294002, Wortmannin,
and Akti or PI3K and Akt mutant reduced CCN4-
increased NF-B promoter activity. These results indicate
that CCN4 increased NF-B activation through the avb5
integrin/PI3K/Akt signaling pathway in human OASFs.
Conclusions
In conclusion, we explored the signaling pathway
involved in CCN4-induced IL-6 production in human
SFs. We found that CCN4 increases IL-6 production by
binding to the avb5 integrin and activating PI3K/Akt
signaling which enhances NF-B transcription activity
and results in the transactivation of IL-6 production.
Furthermore, the discovery of a CCN4/avb5 integrin-
mediated signaling pathway helps us understand the
mechanism of OA pathogenesis and may lead us to
develop effective therapy in the future.
Additional material
Additional file 1: The cell viability of PI3K, Akt, and NF-B inhibitors
in human synovial fibroblasts. OASFs were treated with Wortmannin,
Ly294002, Akt inhibitor, PDTC, or TPCK for 24 hours. The cell viability was
examined by MTT assay. MTT, 3-(4,5-dmethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; OASFs, osteoarthritis synovial fibroblasts;
PDTC, pyrrolidine-dithiocarbamate; TPCK, L-1-tosylamido-2-
phenylenylethyl chloromethyl ketone.
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fluorescein isothiocyanate; IgG: immunoglobulin G; IL: interleukin; mAb:
monoclonal antibody; MMP: matrix metalloproteinase; MTT: 3-(4,5-
dmethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NOV: nephroblastoma
overexpressed; OA: osteoarthritis; OASFs: osteoarthritis synovial fibroblasts;
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the mean; TNF: tumor necrosis factor; TPCK: L-1-tosylamido-2-
Hou et al. Arthritis Research & Therapy 2013, 15:R19
http://arthritis-research.com/content/15/1/R19
Page 11 of 13
phenylenylethyl chloromethyl ketone; WISP-1: WNT-inducible signaling
pathway protein-1.
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